How to Buy Inhibikase Therapeutics Stock
Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. , a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.
Inhibikase Therapeutics stock last closed at $0.60, down 7.69% from the previous day, and has decreased 58.9% in one year. It has underperformed other stocks in the Biotechnology industry by 0.35 percentage points. Inhibikase Therapeutics stock is currently +36.36% from its 52-week low of $0.44, and -60.53% from its 52-week high of $1.52.
As of Mar 20, 2023, there are 25.23M IKT shares outstanding. The market cap of IKT is $15.14M. In the past 24 hours, 403,776 IKT shares were traded.
How to Buy Inhibikase Therapeutics Stock
Not sure how to invest in Inhibikase Therapeutics stock? Here's how.
- Figure out where to buy Inhibikase Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Inhibikase Therapeutics stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Choose your payment method and add your details.
- Research Inhibikase Therapeutics stock: The Inhibikase Therapeutics ticker symbol is IKT. Is Inhibikase Therapeutics stock a good investment? Should you buy shares of IKT? How do IKT's underlying business fundamentals look? Do top analysts think Inhibikase Therapeutics is a good buy? Why has IKT's stock price moved recently? (Hint: Our stock market research tools can help you understand if IKT is a good stock to buy).
- Execute your IKT purchase: Decide if you will purchase IKT shares at the current market price or use a limit order to purchase IKT shares at a specific price.
- Keep an eye on your IKT investment: Create a watchlist to monitor your investment in Inhibikase Therapeutics shares.
Step 1: Figure out where to buy Inhibikase Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy IKT stock.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Technology to Financial Services, New York to London — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by creating an account with eToro now.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the best brokerage, you'll need to fill out some personal details so you can buy IKT stock today.
How to Open a New Account on eToro
- Click here to get started.
- Enter your personal details to open your new brokerage account.
- Send your info by hitting the "Create Account" button.
Step 3: Deposit funds into your brokerage account
Now that you have filled out your info on investing apps, your next step is to transfer the money for your investment:
Check out this video walkthrough if you need help transferring money into your new investment account.
Step 4: Research Inhibikase Therapeutics stock
After you have chosen the best place to buy Inhibikase Therapeutics stock, it's absolutely critical to evaluate their stock prior to buying, so you actually understand the risk as well as the upside.
Inhibikase Therapeutics stock quick numbers
Inhibikase Therapeutics Fundamentals
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on IKT's stock page.
How is IKT stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge IKT's fair value.
Using relative valuations ratios:
- IKT may be undervalued based on its P/B ratio of 0.6x, relative to Biotechnology industry P/B ratio of 4.81x
You can access more valuation analysis on IKT's stock here.
IKT Financial Health Summary
Pros:
- IKT has $26.53M in cash and short term investments. This is enough to cover its annual cash burn of $18.09M.
- IKT has a low debt to equity ratio of 0.14.
- There are more short-term assets than long-term liabilities on the IKT balance sheet.
- IKT has cash burn of 18090712. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the IKT balance sheet.
Cons:
- IKT profit margin has gone down from -335% to -30,438.9% in the past year.
Do analysts think it's a good time to buy Inhibikase Therapeutics stock
Out of 1 Equities analysts who give forecasts on IKT, the consensus analyst rating on IKT is a Hold
Please note that analyst ratings are not recommendations, nor are they investment advice.
Latest IKT Analyst Upgrades/Downgrades
Soumit Roy, a bottom 9% analyst from JonesTrading downgrades IKT to a hold rating, on Nov 16, 2022.
You can dig deeper into what analysts are projecting on the Inhibikase Therapeutics stock forecast page.
IKT Trading Indicators
Is IKT Making Money?
Last year, IKT revenue was $61.82k. Over the past 2 year, IKT's revenue has increased by -71.63% per year. This was slower than the Biotechnology industry average of 50.84%.
You can analyze IKT's earnings and revenue performance here.
Are IKT executives and large shareholders buying or selling the stock?
Over the last 12 months, insiders at IKT have bought more shares than they have sold.
Milton H. Werner, President and CEO of IKT, was the latest IKT insider to buy. They bought $4,000.00 worth of IKT stock on Aug 16, 2022.
Learn more about who owns IKT shares here.
Does IKT stock generate passive income?
No, Inhibikase Therapeutics doesn't provide an income stream by paying out dividends.
IKT Social Trading Data
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Execute your IKT purchase
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a given price, use a limit order.
Press the Open Trade button and eToro will place your order.
If you want more assistance investing in stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your IKT investment
Now that you own some shares in IKT, you'll want to keep up with your new shares.
Put IKT on a watchlist to get notified of important updates regarding your IKT stock.
IKT Feed
How to Buy Stock in Inhibikase Therapeutics
To summarize, here are the 6 steps you need to take to buy Inhibikase Therapeutics stock right now:
- Figure out where to buy Inhibikase Therapeutics stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Research Inhibikase Therapeutics stock
- Execute your IKT purchase
- Keep an eye on your IKT investment
If you require a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Inhibikase Therapeutics, click below.
Trending Stock Buying Guides
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.